Factor VIII inhibitor associated with hepatocellular carcinoma

Neilson, R. F.; Walker, Isobel D.; Robertson, M.

doi:10.1111/j.1365-2257.1993.tb00139.x

Cited by 14 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the recent review based on the histories of 105 cases of AHA in cancers, prostate (25.3%) and lung (15.8%) cancer were more frequent, followed by colon cancer (9.5%)[ 8 ]. There were 3 cases of gastric cancer[ 16 - 18 ] and 2 cases of HCC[ 19 , 20 ]. Another case report for AHA with HCC has also been published[ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Acquired hemophilia A in solid cancer: Two case reports and review of the literature

Saito¹,

Ogasawara²,

Izumiyama³

et al. 2018

WJCC

View full text Add to dashboard Cite

Acquired hemophilia A (AHA) is a rare, hemorrhagic autoimmune disease, whose pathogenesis involves reduced coagulation factor VIII (FVIII) activity related to the appearance of inhibitors against FVIII. Common etiological factors include autoimmune diseases, malignancy, and pregnancy. We report two cases of AHA in solid cancer. The first case is a 63-year-old man who developed peritoneal and intestinal bleeding after gastrectomy for gastric cancer. He was diagnosed with AHA, and was treated with prednisone, followed by cyclophosphamide. In the second case, a 68-year-old man developed a subcutaneous hemorrhage. He was diagnosed with AHA in hepatocellular carcinoma on CT imaging, and treated with rituximab alone. Hemostasis was achieved for both patients without bypassing agents as the amount of inhibitors was reduced and eradicated. However, both patients died within 1 year due to cancer progression. Successful treatment for AHA in solid cancer can be difficult because treatment of the underlying malignancy is also required.

show abstract

Section: Discussionmentioning

confidence: 99%

Acquired hemophilia A in solid cancer: Two case reports and review of the literature

Saito¹,

Ogasawara²,

Izumiyama³

et al. 2018

WJCC

View full text Add to dashboard Cite

show abstract

“…23 Sometimes it precedes tumor diagnosis in months, so it can be labeled in this context as a paraneoplastic syndrome. [23][24][25][26][27][28][29][30][31][32] Sometimes, the detection of an inhibitor takes place after the start of treatment of the specific neoplasm, and it is very difficult to exclude the influence of other factors such as immunosuppressive treatment, chemotherapy and radiotherapy used in its genesis. Another hypothesis to take into account is the non-causal association between neoplasms and AHA, since both are pathologies of advanced age that could coexist.…”

Section: Epidemiologymentioning

confidence: 99%

Acquired Haemophilia A: A Review of What We Know

Mingot‐Castellano¹,

Rodríguez-Martorell²,

Nuñez-Vázquez³

et al. 2022

JBM

View full text Add to dashboard Cite

Autoantibodies against plasma coagulation factors could be developed by some individuals inducing severe and sometimes fatal bleedings. This clinical entity is called acquired haemophilia. It should be suspected in subjects with acute abnormal bleedings, without personal or familiar history of congenital bleeding disorders with an unexplained prolonged aPTT. It is rare disease, although its incidence may be underestimated due to the low knowledge about it by many specialists, the frequent use of anticoagulant or antiplatelet therapies in the affected population that can mask the diagnosis and, sometimes, a so withering effect that avoid its confirmation. Mortality ranges between 9% and 33% depending on the series in the first 2 months after diagnosis. This mortality is attributed in up to 40% of the cases to infections in the context of immunosuppressive treatments used to eliminate the inhibitor. Factor VIII levels below 1% and high inhibitor titers are conditions of worse response rates. Advanced age, patient’s ECOG, and underlying conditions are key prognostic factors for response to treatment and patient survival. To reduce morbidity and mortality in these patients, it is important to have clinical knowledge and access to guidelines to achieve an early diagnosis and to optimize the haemostatic and immunosuppressive treatment. This review aims to contribute to the dissemination of basic concepts on the epidemiology etiopathogenesis, diagnosis, treatment and management of these patients, as well as risk factors to get remission and the longest overall survival to allow individualized care. Especial awareness will be proposed in patients with some underlying conditions like cancer, autoimmune diseases, children, pregnancy or drugs.

show abstract

“…[13][14][15][16][17] In three case reports, AHA was associated with hepatocellular carcinoma (HCC). [18][19][20] According to a review of the literature by Reeves and Key, 11 there are only seven case reports of acquired haemophilia diagnosed before the diagnosis of cancer (2-7 months). We describe a patient in whom first symptoms of haemophilia occurred 2.5 years prior to the diagnosis of cancer.…”

Section: Introductionmentioning

confidence: 99%

Acquired Haemophilia A Associated with Subsequent Hepatocellular Carcinoma

et al. 2018

View full text Add to dashboard Cite

Acquired haemophilia A (AHA) is a rare autoimmune disease caused by antibodies directed against clotting factor VIII. About half of cases are idiopathic, but AHA may also be secondary to autoimmune, dermatologic, or oncologic diseases. In approximately 10% of non-idiopathic cases, the disease occurs after or with the diagnosis of cancer as an extremely rare paraneoplastic syndrome. We describe the case of a 73-year-old male patient diagnosed with AHA and successfully treated with recombinant human activated factor VIIa and immunosuppression. Two and a half years later, however, the disease relapsed and a routine ultrasound revealed a liver tumour that was then diagnosed as hepatocellular carcinoma. We present this case to increase awareness that this life-threatening condition may develop years prior to the diagnosis of cancer.

show abstract

Factor VIII inhibitor associated with hepatocellular carcinoma

Cited by 14 publications

References 2 publications

Acquired hemophilia A in solid cancer: Two case reports and review of the literature

Acquired hemophilia A in solid cancer: Two case reports and review of the literature

Acquired Haemophilia A: A Review of What We Know

Acquired Haemophilia A Associated with Subsequent Hepatocellular Carcinoma

Contact Info

Product

Resources

About